Objective: Although early brain overgrowth is frequently reported in autism spectrum disorder (ASD), the relationship between ASD and head circumference (HC) is less clear, with inconsistent findings from longitudinal studies that include community controls. Our aim was to examine whether head growth in the first 3 years differed between children with ASD from a high-risk (HR) sample of infant siblings of children with ASD (by definition, multiplex), HR siblings not diagnosed with ASD, and low-risk (LR) controls. Method: Participants included 442 HR and 253 LR infants from 12 sites of the international Baby Siblings Research Consortium. Longitudinal HC data were obtained prospectively, supplemented by growth records. Random effects nonlinear growth models were used to compare HC in HR infants and LR infants. Additional comparisons were conducted with the HR group stratified by diagnostic status at age 3: ASD (n ¼ 77), developmental delay (DD; n ¼ 32), and typical development (TD; n ¼ 333). Nonlinear growth models were also developed for height to assess general overgrowth associated with ASD. Results: There was no overall difference in head circumference growth over the first 3 years between HR and LR infants, although secondary analyses suggested possible increased total growth in HR infants, reflected by the model asymptote. Analyses stratifying the HR group by 3-year outcomes did not detect differences in head growth or height between HR infants who developed ASD and those who did not, nor between infants with ASD and LR controls. Conclusion: Head growth was uninformative as an ASD risk marker within this HR cohort.
A utism spectrum disorders (ASD) are among the most common neurodevelopmental disorders, with recent US prevalence estimates at greater than 1 in 100 children. 1 Current early detection strategies focus on behavioral signs that can be reliably detected in the second year of life. 2 However, the identification of biomarkers for ASD could improve the predictive accuracy of behavioral signs alone and help shift surveillance to the first year. 3, 4 Several lines of evidence, including results from neuroimaging [5] [6] [7] [8] and post mortem studies, 9 have identified early brain overgrowth as a distinguishing feature of ASD. Indeed, increased head size has been described in children with autism since Kanner's original case series. 10 Head circumference (HC), available from physician growth records, is correlated with brain volume 11 and thus represents a potential biomarker for ASD. In fact, macrocephaly (HC >97 th percentile) has been reported in many cross-sectional studies of children with ASD, with rates averaging about 20%. [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] Some longitudinal studies have suggested a unique trajectory of head growth in ASD, with a normal or slightly reduced HC at birth, 18, [23] [24] [25] [26] followed by accelerated growth and macrocephaly by around the first birthday, 7, 23, 27, 28 in some cases coinciding with symptom onset 28 and/or correlating with Elder et al. 31 reported that infants from a highrisk sample (younger siblings of children with ASD) were more likely to be diagnosed with ASD if they had increased HC at 12 months and decelerating HC growth rate from 12 to 24 months.
Recent studies, however, suggest the need to re-examine the evidence for head overgrowth in ASD, which is based largely on comparisons with published population norms. A systematic review by Raznahan et al. 32 identified 5 independent longitudinal cohorts of typically developing children that demonstrate trajectories in HC z scores that deviate from Centers for Disease Control and Prevention (CDC) norms 33 in ways similar to those reported in children with ASD, suggesting general norm biases rather than disease-specific biomarkers. The few longitudinal studies of head growth in children with ASD that have incorporated community controls rather than relying on population norms identify only modest differences. Hazlett et al. 7 used a nonlinear (exponential) mixed model to compare head growth trajectories from birth to 35 months in 51 children with ASD, 11 with developmental delay (DD), and 14 typically developing (TD) controls, finding increased growth in the group with ASD relative to the other 2 groups combined. Dissanayake et al. 34 reported increased head growth in 28 children with ASD and IQ >70 compared to 19 TD children of similar mental age, although this reached statistical significance using only a 1-tailed test. In both studies, divergence in head size between groups with and without ASD was not apparent until after the first year. 7, 34 Similarly, a recent birth cohort study from Norway 35 (n ¼ 106,082) that compared children with ASD (n ¼ 376) to others in the population in the first year using mixed effects models found no overall group differences in head growth, although rates of macrocephaly were elevated among boys with ASD (8.7%) compared to other boys (3.3%), presumably because of increased variability in the group with ASD. A US birth cohort study that included 100 children with ASD found no overall ASDrelated differences in head growth based on measurement of HC at 9, 24, and 36 months, based on cross-sectional comparisons at each time point. 36 There is also uncertainty as to whether increased head growth in ASD, when detected, is a component of generalized somatic overgrowth, 34, 37, 38 or is independent of group differences in height and/or weight. 7, 28, 39, 56 In addition, 2 recent studies also reported similar head growth in children with ASD compared to children other developmental or mental health diagnoses 23, 25 ; notably, in 1 of these studies, both groups would have been regarded as having accelerated head growth in the first 18 months if assessed relative to CDC norms. 25 Thus, evidence for increased HC as an ASD-specific risk marker remains inconsistent.
Another key question is whether increased head growth is specific to ASD or, rather, is also expressed in relatives without ASD who share genetic vulnerability. Macrocephaly has been reported in 19% to 31% of parents of probands with ASD 16, 20 and 12% to 16% of siblings. 16, 40 Indeed, a recent analysis of HC from the California Autism Twin Study indicates that rates of macrocephaly are 20% to 27%, with no differences among probands with ASD, concordant and discordant co-twins. 52 Studies reporting HC in relatives have generally not included data regarding other relevant phenotypes (e.g., subthreshold symptoms), so it is difficult to know whether increased rates of macrocephaly are due to nonspecific familial correlations in HC 41 or represent co-segregation of macrocephaly and behavioral symptoms of the "broader autism phenotype," 42, 43 presumably due to the expression of genes involved in susceptibility to ASD.
The objective of this study was to examine whether head growth in the first 3 years differed between high-risk infants who developed ASD versus high-risk infants who did not and low-risk controls. Our longitudinal design allowed prospective as well as retrospective measurement of HC in 1 of the largest samples of children with ASD and nondiagnosed siblings studied to date. all sites was obtained. Data were compiled in a central database at University of California, Davis, where analyses were conducted.
Participants comprised 2 groups: later-born biological siblings of a child with ASD ("high-risk" [HR] ) and infants with no known family history of ASD ("low-risk" [LR] ). The HR infants were recruited from clinics and agencies serving individuals with ASD. The LR infants were recruited by mailings, media announcements, and word-of-mouth. Inclusion criteria for HR infants included a documented diagnosis of DSM-IV-TR autistic disorder, Asperger syndrome, or pervasive developmental disorder not otherwise specified (PDD-NOS; the DSM-IV-TR refers to these conditions collectively as the "pervasive developmental disorders"; in this article, we use the term autism spectrum disorder [ASD] , but recognize that this is not equivalent to ASD as defined in the DSM-5) in the affected sibling (the "proband") and no identified neurological or genetic condition in the infant or proband accounting for the ASD diagnosis (e.g., fragile X syndrome). Additional inclusion criteria were maximum enrollment age of 18 months, minimum outcome assessment age of 35 months, and availability of a clinical best estimate diagnosis (based on the DSM-IV-TR) and the Autism Diagnostic Observation Schedule (ADOS) to assess ASD outcomes. For families with multiple enrolled infants, only the infant recruited at the youngest age was included. Exclusion criteria for both HR and LR infants included prematurity (<37 weeks gestation) and low birth weight (<2,500 g).
Measures
Demographics. Demographic variables included the sex, race, and ethnicity of participating infants, which were reported by parents using categories specified by the National Institutes of Health.
Head Growth. Head growth data were obtained prospectively (measurement of HC during study visits between 6 and 36 months) and retrospectively (review of growth records from the child's community physician). Although our focus was on prospective data, the earliest age of the initial study visit was generally 6 months of age or older; thus, including retrospective data allowed us to assess head growth earlier in the first year. Height/length data (hereafter, height; as per usual methods of assessing growth in young children, length was measured in children <24 months, and height in children 24 months and older) were obtained by the same means. Only HC data with concurrent height measurements were used.
Outcome Assessment and Classification. Outcomes were assessed at 36 months of age by clinical best estimate (CBE), based on DSM-IV-TR, and informed by review of developmental history and administration of the ADOS. The ADOS is a semi-structured, standardized protocol that measures symptoms of ASD and yields an empirically derived cutoff for ASD. 44 Participants were also assessed at 36 months using the Mullen Scales of Early Learning (MSEL), a standardized developmental test for infants and children from birth to 68 months, that measures nonverbal cognitive, language, and motor skills. 45 The sample was divided into outcome groups based on the 36-month assessments. Participants who scored above the ASD cutoff on the ADOS and received a CBE diagnosis of DSM-IV-TR autistic disorder or PDD-NOS were classified as "ASD." Those who did not meet criteria for ASD but had the MSEL composite score and at least 1 subscale-Fine Motor, Visual Reception, Receptive Language, Expressive Language-more than 1.5 SDs below the mean were classified as having developmental delay (DD). Children not meeting criteria for ASD or DD were classified as typically developing (TD).
Data Analysis
We used a random effects 46 nonlinear growth model (i.e., negative exponential model), estimating asymptote, intercept, and the natural log of the rate of HC growth. This approach has effectively modeled biological growth in previous studies, 47, 48 and provides not only a very good fit to the data ( Figure 1 ), but also a clearly appropriate theoretical model to examine asymptotic biological growth such as head circumference. Although linear or quadratic growth models are sometimes used for examining growth in head circumference, 27, 29 neither offers a model that is a plausible model of biological growth for head circumference. Linear models presume infinitely increasing growth, and quadratic models often result in eventual decreases in head circumference, both of which are implausible models at best. In contrast, the asymptotic curves afforded by a negative exponential model are an obvious and significant, if still imperfect, improvement, both empirically and theoretically. The formula
where a represents the asymptote (a maximum size for growth within the time-frame considered), b represents the intercept at age (x) ¼ 0 (the HC at birth), and g represents the anti-log of the rate of change (how rapidly or slowly growth occurs from birth toward the asymptote at 36 months). The 3 growth parameters of asymptote, intercept, and rate of change were estimated for each participant. Then, as each covariate was introduced (e.g., height, sex, outcome), its effect with respect to each growth parameter (asymptote, intercept, and rate of change) was tested for significance just as would be done for a traditional linear model testing for intercept and slope effects. Models were fit using the first-order method of Beal and Sheiner. 49 The analyses proceeded as follows: after fitting the basic growth model, height was added as a timevarying covariate, followed by a dummy-coded variable indicating prospective versus retrospective data collection, and sex. Although we had initially hoped to use site as an additional statistical control in the overall baseline model, the addition of site resulted in 33 additional parameters being estimated (3 growth parameters Â 11 [k-1] sites), which resulted in model convergence problems. However, to assess for site differences, a generalized linear model was run using only prospective measures in high-risk subjects with site explicitly tested after controlling for height and sex. Results revealed no significant site differences for either intercept at 36 months or linear growth over time (all p > .10). Building upon this baseline model, we then compared HR and LR infants (regardless of outcome) on each modeled growth parameter (intercept at birth, rate of growth, and asymptote). Then, the HR group was stratified by 3-year outcomes (i.e., HR-ASD, HR-DD, and HR-TD), with LR as the reference comparison group. This approach allowed us to first compare HR (collapsed across 3-year outcome) to LR infants and then to follow up with an examination of differences among HR-ASD, HR-DD, HR-TD, and LR groups. Next, we assessed potential sex-by-group interactions using product vectors of each outcome group (coded by dummy variables) multiplied by sex. Each model in this sequence was tested against the prior, simpler model by assessing the difference between À2 log likelihood values as a c 2 value with degrees of freedom equal to the difference in model parameters. Finally, we assessed whether HC growth varied across the continuum of ASD symptoms (indexed by ADOS algorithm scores) and developmental level (indexed by the MSEL) at 3 years in the HR group, adjusting for height, method, and sex, as in the previous models.
RESULTS
The final dataset consisted of 695 participants, including 442 HR infants (77 HR-ASD, 32 HR-DD, and 333 HR-TD) and 253 LR infants. LR children with ASD (n ¼ 
Comparison of High-Risk (With and Without
Stratification by 3-Year Outcomes) and Low-Risk Groups The HR group was compared to the LR group, shown in Figure 2 , first as a whole, and then stratified by 36-month outcome (i.e., pairwise comparisons between the HR-ASD, HR-DD, HR-TD, and LR groups). The overall model effect for group was not significant (c 2 ¼ 11. Figure 3 shows the asymptotes for HR-ASD males compared to LR males, and Figure 4 shows the asymptotes of ASD females compared to LR females.
We also assessed whether standard scores on the MSEL subscales or ADOS algorithm scores at 3 years were related to HC growth in the HR group, adjusting for height, method, and sex as in the previous models. Results revealed that none of these variables were related to HC growth parameters.
Analyses of Height
Although height was included in the HC growth models as a time-varying covariate, we conducted a similar set of analyses for height over time as a dependent variable to investigate group differences (i.e., among HR-ASD, HR-DD, HR-TD, and LR infants) in a parameter indexing general growth. As was done for the HC analyses, data collection method and sex were entered as covariates, and both showed a significant effect in terms of model fit. Critically, the main effect for group was not significant (c 2 ¼ 13.00, df ¼ 9, p ¼ .16). The gender-by-group interaction was also not significant (c 2 ¼ 13.00, df ¼ 9, p ¼ .16). However, inspection of specific model parameters revealed a nonsignificant trend toward lower height asymptotes in HR-ASD males (102.06 cm, 95% CI ¼ 98.22-105.91) compared to LR males (106.63 cm, 95% CI ¼ 103.41-109.85, t (190) ¼ 1.89, p ¼ .06), and showed a higher rate of growth À2.95, 95% CI ¼ À3.09 to À2.81) compared to that in the LR males (À3.11, 95% CI ¼ À3.22 to À3.01, t (190) ¼ À1.99, p < .05); that is, the male ASD outcome group initially grew faster in height but ended up shorter. No effects were observed for HR-ASD females compared to LR females, nor to HR-DD, nor HR-TD females.
Analyses of Head Circumference Without Height as Covariate
Given the lack of group differences for growth models of height, and to provide a comparison Overall, the HC growth models without height as a covariate showed less substantial effects, suggesting that the inclusion of height in the previously described growth models served to increase the sensitivity of the models to group differences (i.e., height may act as a suppressor variable).
DISCUSSION
This study examined early head growth in ASD using a prospective design (complemented by retrospective growth records to increase the density of measurement in the first year), and is the first to compare high-risk children with ASD to nondiagnosed high-risk children and community controls using longitudinal growth models.
There are several intriguing findings. First, there are no significant differences in the overall model comparing head growth between HR infants (regardless of outcome) and LR controls in the first 3 years of life. The HR group had a higher asymptote in the nonlinear model relative to the LR group, suggesting that even trends toward risk group differences were due to differences in maximum growth rather than differences in growth rate. Second, there were no differences in any aspect of head growth related to clinical outcome within the HR group (i.e., no differences among HR-ASD, HR-DD, and HR-TD subgroups, nor any relationship with MSEL or ADOS scores), suggesting that the modest risk group difference in asymptote was not specific to participants with ASD. Third, although the overall groupby-sex interaction did not reach statistical significance, there were interesting trends toward higher asymptotes in HR males (regardless of ASD outcome) compared to LR males, and towards lower asymptotes in HR females with ASD compared to other HR and LR infants. Overall, head growth was largely uninformative as an ASD risk marker within this HR cohort. Finally, contrary to some recent studies, 37, 38 we did not find evidence of general somatic overgrowth in children with ASD, relative to other HR infants or to LR controls.
Our findings are broadly consistent with a recent systematic review that identified 11 published longitudinal studies that compared HC in young children in ASD to population (CDC) norms or community controls. 32 All 4 studies comparing HC growth in ASD to CDC norms reported substantial differences in the first year, 23, 24, 28, 30 whereas only 4 of 7 studies comparing children with ASD to community controls 7, 27, 29, 34 identified periods of accelerated head growth. Moreover, effect sizes in studies with community controls varied by analytic approach. 32 The 2 studies 27,29 that modeled linear growth trajectories within selected age bands reported robust evidence of accelerated HC growth in ASD in the first year, similar to studies that include multiple cross-sectional group comparisons. 38 In contrast, studies using nonlinear approaches (arguably better suited to modeling biological growth processes 47 ) reported either small differences emerging in the second year 7, 34 or no differences. 25, 50 Only 1 previous study 31 has examined head growth during infancy in ASD in a HR cohort (n ¼ 77), reporting accelerated growth as indexed www.jaacap.org by z scores relative to CDC norms and using separate linear models in the first and second years. Growth data were from retrospective growth records and diagnostic outcomes were not reported. Although there was a modest relationship between 12-month z scores and socialcommunication symptoms, positive z scores and inclining slopes were observed at all symptom levels, emphasizing the limitations of relying on population norms to characterize head growth differences in ASD.
It is worth emphasizing that although we did not identify differences in HC growth that were specific to ASD, there was a modest difference between the HR group as a whole and community controls in final growth level, indexed by the model asymptote. Thus, increases in head growth may be an endophenotype for ASD 51 related to genetic vulnerability, but not specifically associated with ASD symptoms or diagnosis within this HR cohort. Indeed, previous studies have reported elevated rates of macrocephaly in first-degree relatives of children with ASD. 16, 20, 40 Moreover, recent analyses from the California Autism Twin Study indicated similar rates of macrocephaly in affected (n ¼ 53) and unaffected (n ¼ 149) co-twins, with similar familial correlation in HC in concordant and discordant twin pairs. 52 Our study has a number of strengths, including the large sample size and relative density of longitudinal data, many of which were collected prospectively. Comparison of children with ASD to other HR and LR participants, examination of the relationship between head growth and ASD based on both categorical outcomes and a quantitative measure of symptom severity, and distinguishing head growth from general somatic (i.e., height) growth are other unique features that lend further weight to the overall findings. However, there are several potential limitations. First, findings from HR infants who developed ASD (by definition, multiplex cases) do not necessarily generalize to other children with ASD. There may be etiologic differences (e.g., higher rates of rare genomic variants 53 ) that index processes involved in early brain development and somatic growth in HR individuals with ASD. Further comparison of longitudinal head growth as a potential biomarker of ASD in single and multiple incidence families is warranted, as different sets of genetic and environmental factors may contribute etiologically. Second, although head growth in our HR sample was not associated with ASD outcomes, this does not imply that accelerated brain growth during infancy would be uninformative. Hazlett et al. 54 did not detect differences in brain volume at 6 months related to ASD outcomes in 98 HR infants, but comparisons at subsequent time points involving that cohort are still forthcoming. Finally, despite our large sample, ASD is characterized by marked etiologic and phenotypic heterogeneity, and we cannot exclude the possibility that early acceleration in head growth is associated with ASD in a subgroup of HR infants. Indeed there are examples of specific genetic subtypes of ASD (e.g., PTEN mutation) that are associated with marked head and brain overgrowth. 55 However, head growth was not predictive of ASD within our HR cohort as a whole, nor was there evidence that children with ASD were overrepresented among outliers in the first year (i.e., >90 th percentile; >97 th percentile; data available on request). We also acknowledge that the HR-DD group is relatively small for group comparisons, although analyses treating MSEL subscales as continuous variables also failed to find association with head growth trajectories. Thus, although reports of macrocephaly in ASD date back to Kanner's original case study, 10 further data are still needed on the relationship between early head and brain growth and risk of ASD within familial HR samples. The current study suggests that although there are modest differences in early head growth between HR and LR groups, these differences are not specifically predictive of ASD. &
